U.S. Consumer Genomics Market size, Industry Report, 2033
The U.S. consumer genomics market size was valued at USD 485.90 million in 2023 and is projected to surpass around USD 4,489.22 million by 2033, registering a CAGR of 24.9% over the forecast period of 2024 to 2033.
The genomic analysis field simplify consumer DNA analysis, supplementing market growth. Advancements in genetic research help raise awareness among physicians and consumers about the use of gene-based testing. Genomics testing enables the determination of common traits by studying a DNA molecule, makes predictions about health, and offers evidence of a person’s ancestry. Rising awareness about DNA testing has driven the adoption rate, providing healthy growth prospects for implementing DNA tests in home settings.
U.S. accounted for over 31.1% of the global consumer genetics market in 2023. Recently, there's been a surge in the demand for genetic testing services offered directly to consumers. These tests usually examine a person's DNA to reveal information about potential health risks, genetic characteristics, and lineage. As the consumer genomics sector grows, several companies are providing DNA tests directly to customers by which they have access to their genetic information without involving the healthcare professional. However, it's essential to carefully assess the reliability and quality of these services before opting for any testing, given the current lack of stringent regulation over direct-to-consumer genetic testing firms.
Following the outbreak of the COVID-19 pandemic, public health concerns have intensified, leading to a surge in interest in advanced methods such as consumer genomics. This escalating consciousness about health matters and the significance of genetics has fueled the continuous expansion of the market. A primary element propelling this growth is the increasing emphasis on DNA-centric research and development (R&D) initiatives, especially in bioinformatics, for developing diagnostic instruments and effective treatments, including those pertinent to COVID-19.
The market's growth is chiefly driven by various elements, such as a rise in interest from consumers and doctors in direct-to-consumer (DTC) kits, technological advancements, the broadening scope of consumer genomics applications, favorable government policies, and the escalating trend of personalized genomics. For instance, the popularity of DTC tests significantly rose in 2022, as they could be bought without a doctor's prescription, making them more readily available and user-friendly for the public.
Growth in the variety of uses for direct-to-consumer (DTC) genetic tests greatly contributes to the market's development. Genetic testing covers numerous services, such as tracing ancestry, determining race, and exploring familial connections. The wide range of applications has resulted in a higher adoption rate in clinical settings. Moreover, reliable consumer genetics tests are applicable across clinical, genealogical, forensic, research, sports, nutrition, and numerous other sectors. Many companies provide adaptable DTC tests for these diverse fields.
Market growth is anticipated to receive additional backing from notable advancements in product innovation and partnerships between major industry participants. An example is July 2022, when 1health.io Inc. notably broadened its testing capacities within clinical and direct-to-consumer domains. Furthermore, the company collaborated with Apollo Health Group to expand the clinical market for Apollo's advanced Next-Generation Sequencing (NGS) assays, encompassing pharmacogenetics screenings (PGx) and hereditary cancer genetic screenings (CGx). These developments are playing a significant role in driving the expansion of the market.
Several companies, including My Gene Diet, Halo Health International, and Smart DNA, offer customized diet services and meal plans based on an individual's genetic makeup. The popularity of direct-to-consumer (DTC) personalized genomic testing is on the rise, fueled by the accessibility of these tests, with prices varying from as low as USD 100 to over USD 2000, depending on the test's intricacy and scope. Companies like My Gene Diet, Smart DNA, and Halo Health International offer customized dietary services and meal plans based on a person's genetic makeup. The popularity of personalized genomic testing sold directly to consumers (DTC) is on the rise, fueled by the cost-effectiveness of these tests. The prices vary widely, from as little as USD 100 to more than USD 2000, depending on the intricacy and extent of the tests.
| Report Attribute | Details |
| Market Size in 2024 | USD 606.89 million |
| Market Size by 2033 | USD 4,489.22 million |
| Growth Rate From 2024 to 2033 | CAGR of 24.9% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Application |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled |
Ancestry; Gene By Gene, Ltd. (FamilyTree DNA); 23andMe, Inc.; Color Health, Inc; Myriad Genetics, Inc; Mapmygenome; Helix OpCo LLC; MyHeritage Ltd.; Pathway Genomics; Veritas; Amgen, Inc.; Diagnomics, Inc.; Toolbox Genomics; SomaLogic, Inc.; inui Health (formerly Scanadu); QuickCheck Health; Illumina, Inc. |
Genetic relatedness dominated the market and held the largest revenue share of 19.13% in 2023. Paternity and maternity tests, often available online, are expected to increase the market growth. Many customers use DTC genetic testing to learn about their genetic traits and find distant relatives. Moreover, a 2021 study by the University of Cambridge found that genome sequencing from a single blood test could detect 31% more rare genetic disorders than standard tests. The U.S. is expected to have almost 2 million new cancer cases in 2022, as estimated by the American Cancer Society. The International Agency for Research on Cancer (IARC) estimates that over 30 million cancer cases will remain undiagnosed by the year 2040. Therefore, identifying potential cancer risks and determining the hereditary nature of the disease through genetic testing is crucial.
The lifestyle, wellness, & nutrition segment is expected to grow at the fastest CAGR of 26.6% during the forecast period. Numerous companies, including Natures Remedies Ltd, Pathway Genomics, Helix, Toolbox Genomics, and others, provide nutrigenetic testing services. These services encompass fitness tests and extend to diet, wellness, and several nutrition plans. Some of these firms also specialize in delivering personalized diets, meals, and even plans for food supplements. Genetic tests based on lifestyle and nutrition are viewed as promising and are broadly accessible to aid with diet and lifestyle strategies.
The U.S. consumer genomics market is characterized by intense competition, with a major share being held by numerous manufacturers. Market players employ key business strategies such as product introductions, approvals, strategic takeovers, and innovations to sustain and expand their global presence. For instance, Grifols, in May 2023, introduced AlphaIDAt Home, enabling American consumers to self-test for genetic COPD.
U.S. Consumer Genomics Market Top Key Companies:
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. Consumer Genomics market.
By Application
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Application
1.2.2. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. nova one advisor internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in U.S.
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Application Outlook
2.3. Competitive Insights
Chapter 3. U.S. Consumer Genomics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rise in interest of consumers & physicians in DTC kits & consequent rise in sales of DNA test kits
3.2.1.2. Increase in access to DTC services due to reducing cost of genotyping
3.2.1.3. Expansion in applications of DTC genetics
3.2.1.3.1. Health testing
3.2.1.3.2. Ancestry
3.2.1.3.3. Genetic relatedness
3.2.1.4. Significant investments & initiatives by companies to maintain their competitive edge in the market
3.2.1.5. Growing trend of personalized genomics
3.2.2. Market restraint analysis
3.2.2.1. Ethical and clinical issues pertaining to the use of DTC products & personalized treatment
3.2.2.2. Regulatory challenges pertaining to the use of DTC genetic tests
3.3. U.S. Consumer Genomics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces
3.3.1.1. Threat of new entrant
3.3.1.2. Threat of substitues
3.3.1.3. Bargaining power of buyers
3.3.1.4. Bargaining power of suppliers
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political & legal landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
Chapter 4. U.S. Consumer Genomics Market: Application Estimates & Trend Analysis
4.1. U.S. Consumer Genomics Market: Application Dashboard
4.2. U.S. Consumer Genomics Market: Application Movement Analysis
4.3. U.S. Consumer Genomics Market Size & Forecasts and Trend Analyses, 2021 to 2033
4.4. Genetics Relatedness
4.4.1. Market estimates and forecasts 2021 to 2033
4.5. Ancestry
4.5.1. Market estimates and forecasts 2021 to 2033
4.6. Lifestyle, Wellness, & Nutrition
4.6.1. Market estimates and forecasts 2021 to 2033
4.7. Diagnostics
4.7.1. Market estimates and forecasts 2021 to 2033
4.8. Sports Nutrition & Health
4.8.1. Market estimates and forecasts 2021 to 2033
4.9. Reproductive Health
4.9.1. Market estimates and forecasts 2021 to 2033
4.10. Personalized Medicine & Pharmacogenetic Testing
4.10.1. Market estimates and forecasts 2021 to 2033
4.11. Others
4.11.1. Market estimates and forecasts 2021 to 2033
Chapter 5. Competitive Landscape
5.1. Recent Developments & Impact Analysis, By Key Market Participants
5.2. Company/Competition Categorization
5.3. Vendor Landscape
5.3.1. List of key distributors and channel partners
5.3.2. Key customers
5.3.3. Key company market share analysis, 2023
5.3.4. Ancestry
5.3.4.1. Company overview
5.3.4.2. Financial performance
5.3.4.3. Product benchmarking
5.3.4.4. Strategic initiatives
5.3.5. Gene By Gene, Ltd. (FamilyTree DNA)
5.3.5.1. Company overview
5.3.5.2. Financial performance
5.3.5.3. Product benchmarking
5.3.5.4. Strategic initiatives
5.3.6. 23andMe, Inc.
5.3.6.1. Company overview
5.3.6.2. Financial performance
5.3.6.3. Product benchmarking
5.3.6.4. Strategic initiatives
5.3.7. Color Health, Inc
5.3.7.1. Company overview
5.3.7.2. Financial performance
5.3.7.3. Product benchmarking
5.3.7.4. Strategic initiatives
5.3.8. Myriad Genetics, Inc
5.3.8.1. Company overview
5.3.8.2. Financial performance
5.3.8.3. Product benchmarking
5.3.8.4. Strategic initiatives
5.3.9. Mapmygenome
5.3.9.1. Company overview
5.3.9.2. Financial performance
5.3.9.3. Product benchmarking
5.3.9.4. Strategic initiatives
5.3.10. Helix OpCo LLC
5.3.10.1. Company overview
5.3.10.2. Financial performance
5.3.10.3. Product benchmarking
5.3.10.4. Strategic initiatives
5.3.11. MyHeritage Ltd.
5.3.11.1. Company overview
5.3.11.2. Financial performance
5.3.11.3. Product benchmarking
5.3.11.4. Strategic initiatives
5.3.12. Pathway Genomics
5.3.12.1. Company overview
5.3.12.2. Financial performance
5.3.12.3. Product benchmarking
5.3.12.4. Strategic initiatives
5.3.13. Veritas
5.3.13.1. Company overview
5.3.13.2. Financial performance
5.3.13.3. Product benchmarking
5.3.13.4. Strategic initiatives
5.3.14. Amgen, Inc.
5.3.14.1. Company overview
5.3.14.2. Financial performance
5.3.14.3. Product benchmarking
5.3.14.4. Strategic initiatives
5.3.15. Diagnomics, Inc.
5.3.15.1. Company overview
5.3.15.2. Financial performance
5.3.15.3. Product benchmarking
5.3.15.4. Strategic initiatives
5.3.16. Toolbox Genomics
5.3.16.1. Company overview
5.3.16.2. Financial performance
5.3.16.3. Product benchmarking
5.3.16.4. Strategic initiatives
5.3.17. SomaLogic, Inc.
5.3.17.1. Company overview
5.3.17.2. Financial performance
5.3.17.3. Product benchmarking
5.3.17.4. Strategic initiatives
5.3.18. inui Health (formerly Scanadu)
5.3.18.1. Company overview
5.3.18.2. Financial performance
5.3.18.3. Product benchmarking
5.3.18.4. Strategic initiatives
5.3.19. QuickCheck Health
5.3.19.1. Company overview
5.3.19.2. Financial performance
5.3.19.3. Product benchmarking
5.3.19.4. Strategic initiatives
5.3.20. Illumina, Inc.
5.3.20.1. Company overview
5.3.20.2. Financial performance
5.3.20.3. Product benchmarking
5.3.20.4. Strategic initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers